Rheumatology Advance Access originally published online on July 25, 2008
Rheumatology 2009 48(2):93-95; doi:10.1093/rheumatology/ken294
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
EDITORIALS |
Polymyalgia rheumatica vs late-onset rheumatoid arthritis
1Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy
Correspondence to: M. Cutolo, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Viale Benedetto XV, 6, 16132 Genova, Italy. E-mail: mcutolo@unige.it
| The first 150 words of the full text of this article appear below. |
Polymyalgia rheumatica differs from RA
Polymyalgia rheumatica (PMR) is a well-defined acute musculoskeletal inflammation of ageing people and characterized by clinical symptoms that may create some difficulties in the differential diagnosis with late (elderly) onset RA (LO-RA or EO-RA, respectively) as well as with LO-RA with PMR-like onset (LO-RA/PMR) [1].
PMR as an inflammatory condition of multifactorial aetiology is generally characterized at least at the beginning by aching and stiffness in the shoulder and in the pelvic girdles. It occurs in people over the age of 50–60 yrs, and it usually responds rapidly to low doses of glucocorticoids and has a favourable prognosis. Genetic causes and polymorphisms of additional genes involved in the initiation and regulation of inflammatory reaction have been considered to be possible susceptibility factors for PMR [2]. In particular, TNF-
, and IL-1 receptor antagonist (IL-1Ra) gene polymorphisms are predisposing factors and may be implicated in the pathogenesis
Genetic and clinical differences
Different markers of inflammation
Hormonal differences
Treatments
Conclusions